Parion Sciences Announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to Accelerate the Development of Novel CF Treatment

Paul Boucher
Parion Sciences, President
[email protected]

Expanded Collaboration Supports Phase 2 Clinical Trial Initiation of First-In-Class ENaC Inhibitor for the Treatment of Cystic Fibrosis

Durham, NC (September 16, 2014) – Parion Sciences today announced it has received a $3 million award from Cystic Fibrosis Foundation Therapeutics (CFFT) to support the development of P-1037, Parion’s new investigational treatment for cystic fibrosis (CF). This award will accelerate the initiation of a phase 2 trial for P-1037 in people with CF. Parion intends to begin trial enrollment in early 2015 and will include people with CF regardless of an individual’s genetic mutation. P-1037 inhibition of sodium channels in the airways is expected to promote fluid secretion and re-hydrate the mucus layers, thus restoring airway clearance, reducing infection and improving lung function.

“The Parion team appreciates all of the support from the Cystic Fibrosis Foundation as we advance our novel programs,” stated Paul Boucher, President of Parion Sciences. “With this funding award, Parion is rapidly advancing our ENaC inhibitor, P-1037, toward initiating our phase 2 clinical trial in cystic fibrosis patients. Additionally, CFFT’s extension of our CFTR program validates the promising progress made by our research team”.